Triple mode of action of flecainide in catecholaminergic polymorphic ventricular tachycardia

Cardiovascular Research

Volumn 98, Issue 2, 2013, Pages 326-327

  Steele, Derek S ^a   Hwang, Hyun Seok ^b   Knollmann, Björn C ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLECAINIDE; ISOPRENALINE; LIDOCAINE; PROCAINAMIDE; PROPAFENONE; RYANODINE RECEPTOR 2; SODIUM CHANNEL BLOCKING AGENT; SODIUM ION; TETRODOTOXIN;

BETA ADRENERGIC STIMULATION; CALCIUM SIGNALING; CALCIUM TRANSPORT; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CELL MEMBRANE PERMEABILITY; CHANNEL GATING; CLINICAL EFFECTIVENESS; HEART DEPOLARIZATION; HEART MUSCLE CELL; HEART PACING; HUMAN; LETTER; NONHUMAN; PRIORITY JOURNAL; PURKINJE FIBER; SARCOPLASMIC RETICULUM; SODIUM TRANSPORT;

ANIMALS; CALCIUM SIGNALING; FLECAINIDE; MALE; SARCOLEMMA; VOLTAGE-GATED SODIUM CHANNEL BLOCKERS;

EID: 84877302277     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt059     Document Type: Letter

References (17)

1. Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 2009;15:380-383.
2. van der Werf C, Kannankeril PJ, Sacher F, Krahn AD, Viskin S, Leenhardt A et al. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol 2011;57:2244-2254.
3. Watanabe H, van der Werf C, Roses-Noguer F, Adler A, Sumitomo N, Veltmann C et al. Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. Advance Access published Dec 31, 2012, doi:10.1016/j.hrthm.2012.12.035
4. Hilliard FA, Steele DS, Laver D, Yang Z, Le Marchand SJ, Chopra N et al. Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass. J Mol Cell Cardiol 2010;48: 293-301.
5. Liu N, Denegri M, Ruan Y, Avelino-Cruz JE, Perissi A, Negri S et al. Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity. Circ Res 2011;109:291-295.
6. Watanabe H, Steele DS, Knollmann BC. Mechanism of antiarrhythmic effects of flecainide in catecholaminergic polymorphic ventricular tachycardia. Circ Res 2011; 109:712-713.
7. Hwang HS, Knollmann BC. Calcium overload reduces flecainide efficacy against spontaneous calcium release. Biophys J 2012;102:102a (Abstract).
8. Sikkel MB, Collins TP, Rowlands C, Shah M, O'Gara P, Williams AJ et al. Flecainide reduces Ca2+ spark and wave frequency via inhibition of the sarcolemmal sodium current. Cardiovasc Res 2013;98:286-296.
9. Diaz ME, Cook SJ, Chamunorwa JP, Trafford AW, Lancaster MK, O'Neill SC et al. Variability of spontaneous Ca2+ release between different rat ventricular myocytes is correlated with Na+-Ca2+ exchange and [Na+]i. Circ Res 1996;78:857-862.
10. Rosen MR, Danilo P Jr. Effects of tetrodotoxin, lidocaine, verapamil, and AHR-2666 on Ouabain-induced delayed afterdepolarizations in canine Purkinje fibers. Circ Res 1980;46:117-124.
11. Galimberti ES, Knollmann BC. Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin. J Mol Cell Cardiol 2011;51:760-768.
12. Lee YS, Maruyama M, Chang PC, Park HW, Rhee KS, Hsieh YC et al. Ryanodine receptor inhibition potentiates the activity of Na channel blockers against spontaneous calcium elevations and delayed afterdepolarizations in Langendorff-perfused rabbit ventricles. Heart Rhythm 2012;9:1125-1132.
13. Hwang HS, Hasdemir C, Laver D, Mehra D, Turhan K, Faggioni M et al. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol 2011;4:128-135.
14. Liu N, Napolitano C, Venetucci LA, Priori SG. Flecainide and antiarrhythmic effects in a mouse model of catecholaminergic polymorphic ventricular tachycardia. Trends Cardiovasc Med 2012;22:35-39.
15. Hwang HS, Galimberti ES, Knollmann BC. Slow diffusion across cell membrane delays onset of RyR2-channel block and Ca wave suppression by flecainide in intact myocytes. Biophys J 2011;100:416a (Abstract).
16. Latini R, Cavalli A, Maggioni AP, Volpi A. Flecainide distribution in human tissues. Br J Clin Pharmacol 1987;24:820-822.
17. Zhou Q, Xiao J, Jiang D, Wang R, Vembaiyan K, Wang A et al. Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ release. Nat Med 2011;17:1003-1009.